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Identity 
Other names: ERYF1; GF1; NFE1 
HGNC (Hugo): GATA1 
Location: Xp11.23 
Location (base pair): start at 48,401,210 bp from pter, 
ends at 48,408,967 bp from pter. 
DNA/RNA 
Description 
Genomic sequence 7,757 bases, mRNA six exons (five 
coding) 1497bp. Plus strand. 
Protein 
Description 
The full length GATA1 protein is 413 amino acids; 
42.7 KDa. However two major protein isoforms are  
formed by alternative splicing of the mRNA and 
alternative translation initiation sites as shown in the 
figure. The shorter GATA1 protein (GATA1s) lacks 
the first 83 aa. ("The N-terminal activation domain 
AD"). GATA1s is less active in activation of 
megakaryocytic promoters. Both proteins contain two 
Zinc finger domains mediating protein interactions and 
DNA binding. 
Expression 





Transcription Factor, essential for eryhtroid and 
megakaryocytic development. 
Homology 
A member of the family of GATA proteins. 
 
Alternative models for generation of GATA1 isoforms. The full GATA1 protein can only be translated from the full GATA1 mRNA, 
whereas the GATA1s protein can be translated either from the full gata-1mRNA or from the shorter splice variant in which exon 2 is 
skipped. 











Implicated in germline mutations in the N- Zinc finger 
domain that mediates the interaction with FOG1 and/or 
binding to DNA, cause X-linked Dyserythropoietic 
anemia with thrombocytopenia. The syndrome can be 





Acquired somatic mutations in GATA1 occur in 
virtually all children with Down Syndrome (DS) and 
congenital transient myeloproliferative syndrome 
(TMD) or acute megakaryocytic leukemia (AMKL, 
M7-ANLL). The mutations have also been detected in 
umbilical cord blood of DS patients and in fetal liver of 
aborted DS embryos. The mutations occur in-utero 
probably during fetal liver hematopoiesis. They consist 
of insertions, deletions and base substitution in exon 2 
and vicinity and all result in elimination of the full 
length GATA1 protein with preservation of the 
GATA1s isoform. The presence of GATA1s in the 
absence of full length GATA1 blocks megakaryocytic 
differentiation and promote proliferation of 
megakaryoblasts. The genes on chromosome 21 that 
promote this abnormality are unknown. GATA1 
mutations are almost always associated with the M7 
leukemia in DS although they were also described in a 
pair of twins with acquired trisomy 21 and in one adult 
non DS patient with M7. The down-regulations of 
genes regulated by GATA1 may explain the exquisite 
sensitivity of DS leukemic blasts to ACA-C. 
 
Legend: Example to the distribution of the mutations in children 
with M7 and DS described in Rainis et al. 
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